



9/30/04

1FW

PTO/SB/21 (04-04)

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

10/699,517

Filing Date

October 31, 2003

First Named Inventor

Schenk, Dale B.

Art Unit

1646

Examiner Name

Unassigned

Attorney Docket Number

015270-008920US

ENCLOSURES (Check all that apply)☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Supplemental Information

Disclosure Statement (2 pp.)

PTO/SB08A (1 pg.) PTO/SB08B (1 pg.)

*references AA-AO

☐

Certified Copy of Priority Document(s)

☐Response to Missing Parts/
Incomplete Application☐Response to Missing Parts
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a
Provisional Application☐Power of Attorney, Revocation
Change of Correspondence Address☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐After Allowance Communication
to Technology Center (TC)☐Appeal Communication to Board
of Appeals and Interferences☐Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Other Enclosure(s) (please
identify below):

Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit
Account 20-1430.

*Not included in the "Total Number of Pages In This Submission"

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Townsend and Townsend and Crew LLP

Rosemarie L. Celli

Reg. No. 42,397

Signature

Date

September 28, 2004

CERTIFICATE OF TRANSMISSION/MAILING

Express Mail Label: EV 337295142 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date August 5, 2004 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Daniel Miranda

Signature

Date

September 28, 2004



PATENT
Attorney Docket No.: 015270-008920US
Client Reference No.: 334-US-NEW2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 10/699,517

Filed: October 31, 2003

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Examiner: Unassigned

Art Unit: 1646

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rosemarie L. Celli". The signature is fluid and cursive, with a large initial "R" and a stylized "C".

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
60307804 v1



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1646
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AF	BODLES et al., "Toxicity of non-A β component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β -sheet structure and fibrils," <u>Eur J. Biochem.</u> , 267:2186-2194 (2000).	
	AG	CAO et al., "Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease," Program No. 594.13, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience, 2002.	
	AH	CULVENOR et al., "Non-A β Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and α -Synuclein Are Not Associated with A β Amyloid," <u>Am. J. Pathology</u> , 155(4):1173-1181 (1999).	
	AI	HASHIMOTO et al., "Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease," <u>Brain Pathology</u> , 9:707-720 (1999).	
	AJ	HSU et al., " α -Synuclein Promotes Mitochondrial Deficit and Oxidative Stress," <u>Am. J. Pathology</u> , 157(2):401-410 (2000).	
	AK	JENSEN et al., "Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide," <u>Biochem. J.</u> , 310(Pt 1):91-94 (1995).	
	AL	MASLIAH et al., "Dopaminergic Loss and Inclusion Body Formation in α -Synuclein Mice: Implications for Neurodegenerative Disorders," <u>Science</u> , 287:1265-1268 (2000).	
	AM	NCBI database search result for P37840 Alpha-synuclein conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&DB=protein&list_uids=58	
	AN	NCBI database search result for NP_009292 synuclein, alpha conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list_uids=68	
	AO	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," <u>PNAS</u> , 90:11282-11286 (1993).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.